<DOC>
	<DOCNO>NCT00491127</DOCNO>
	<brief_summary>The purpose study evaluate efficacy gemcitabine cisplatin dexamethasone patient aggressive non-Hodgkin 's lymphoma previously progress first line chemotherapy anthracyclines .</brief_summary>
	<brief_title>Cisplatin With Gemcitabine With Dexamethasone Patients With Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<criteria>The patient must histological diagnosis aggressive nonHodgkin â€™ lymphoma include follow subcategories WHO classification : Diffuse large Bcell lymphoma variant ( immunoblastic , Burkittlike , sclerosis mediastinum , large Bcell MALT , rich Tcells anaplastic Bcell lymphoma ) Peripheral Tcell lymphoma Anaplastic lymphoma large Tcells /null cell Patients eligible document evidence progression prior firstline chemotherapy contain anthracyclines associate Rituximab . Patients refractory disease first line treatment also eligible . ECOG PS ( performance status ) less equal 2 Presence bidimensionally measurable disease accordance WHO criteria . Involvement CNS . Any medical condition contraindicates degree hydration require safe use cisplatin . Intermediate degree lymphoma derive malignant transformation previous lowgrade lymphoma . Active infection ( opinion investigator ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>